PROK
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp. (PROK) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | F (0.3) | D (1.2) | D (1.5) | C (2.2) | C+ (2.6) | D+ (1.6) |
| 2026-11-07 | F (0.3) | D (1.4) | D (1.3) | C- (2.1) | C+ (2.7) | D+ (1.6) |
| 2026-10-31 | F (0.1) | D (1.4) | D (1.3) | C (2.2) | C+ (2.7) | D+ (1.6) |
| 2026-10-24 | F (0.1) | D (1.4) | D (1.3) | C (2.2) | C+ (2.6) | D+ (1.5) |
| 2026-10-17 | F (0.2) | D (1.4) | D (1.3) | C- (2.1) | C+ (2.6) | D+ (1.5) |